+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Central Nervous System Therapeutics Market By Drug Class By Application By Route of Administration By End Users By Distribution Channel By Region, Competition Forecast & Opportunities, 2027

  • PDF Icon

    Report

  • 113 Pages
  • September 2022
  • Region: Global
  • TechSci Research
  • ID: 5401743
Free Webex Call
10% Free customization

Factors Such as the Rise in Prevalence of Central Nervous System Disorders and Advancements in Therapeutics and Diagnostics of Central Nervous System Disorders are Driving the Demand for the Global Central Nervous System Therapeutics Market.

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The global central nervous system therapeutics market is anticipated to grow at a strong CAGR during the forecast period, 2023-2027. Factors such as the rise in prevalence of central nervous system disorders and advancements in therapeutics and diagnostics of central nervous system disorders are driving the demand for the global central nervous system therapeutics market. Growing diagnosis rates in developed and emerging economies are presenting a large patient pool that requires treatment. Also, the initiatives by the government authorities, healthcare systems, non-profit organizations, and market players to create awareness about neurological disorders are further expected to support the growth of the global central nervous system therapeutics market in the forecast period.

The global central nervous system therapeutics market is segmented into drug class, application, route of administration, end user, distribution channels, regional distribution, and competitive landscape. Based on application, the market is fragmented into neurovascular diseases, mental health and trauma, neurodegenerative diseases, infectious diseases, cns cancer, and others. Neurodegenerative diseases are expected to capture the highest market share during the forecast period, 2023-2027. The high cost of treatment of neurodegenerative diseases and the increased prevalence of neurodegenerative diseases such as Parkinson’s disease, multiple sclerosis, and Alzheimer’s disease are driving the segment demand.

North America is expected to dominate the global central nervous system therapeutics market during the forecast period. The presence of key market players in the region and the initiatives taken by market players to develop new technologies are infleuncing the market demand. Also, the rising incidence of mental health conditions and neurological disorders is expected to propel the market demand in the forecast period.

The major market players operating in the global central nervous system therapeutics market are Eli Lilly and Company Ltd., Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., GlaxoSmithKline PLC, Otsuka Holdings Co. Ltd., Johnson & Johnson Services Inc., Sanofi SA, Bristol Myers Squibb Pharmaceuticals Ltd., Bayer AG, Amgen Inc., among others.

Years considered for this report:

  • Historical Years: 2017 - 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 - 2027

Objective of the Study:

  • To analyze and forecast the market size of Global central nervous system therapeutics market from 2017 to 2021.
  • To estimate and forecast the market size of Global central nervous system therapeutics market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global central nervous system therapeutics market based on drug class, application, route of administration, end user, distribution channel, and regional distribution.
  • To identify dominant region or segment in the global central nervous system therapeutics market.
  • To identify drivers and challenges for global central nervous system therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global central nervous system therapeutics market.
  • To identify and analyze the profile of leading players operating in global central nervous system therapeutics market.
  • To identify key sustainable strategies adopted by market players in global central nervous system therapeutics market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufactures which could not be identified due to the limitations of secondary research. The publisher analyzed the manufactures, distribution channels and presence of all major players across the country.

The publisher calculated the market size of global central nervous system therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:

  • Central nervous system therapeutics manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of central nervous system therapeutics and services and other stakeholders
  • Organizations, forums, and alliances related to central nervous system therapeutics
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global central nervous system therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Class:

  • Analgesics
  • Anesthetics
  • Anticonvulsants
  • Antiepileptics
  • Anti-Parkinson Agents
  • Others

Market, By Application:

  • Neurovascular Diseases
  • Mental Health and Trauma
  • Neurodegenerative Diseases
  • Infectious Diseases
  • CNS Cancer
  • Others

Market, By Route of Administrations:

  • Oral
  • Parenteral
  • Others

Market, By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others

Market, By Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Market, By Region:

  • North America
  • APAC
  • Europe
  • MEA
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global central nervous system therapeutics market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Central Nervous System Therapeutics Market4. Executive Summary5. Voice of Customer
6. Global Central Nervous System Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others)
6.2.2. By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others)
6.2.3. By Route of Administration (Oral, Parenteral, Others)
6.2.4. By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others)
6.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
6.2.6. By Company (2021)
6.2.7. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
6.3. Product Market Map
7. North America Central Nervous System Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Application
7.2.3. By Route of Administration
7.2.4. By End Users
7.2.5. By Distribution Channel
7.2.6. By Country (United States; Canada; Mexico)
7.3. North America: Country Analysis
7.3.1. United States Central Nervous System Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Application
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End Users
7.3.1.2.5. By Distribution Channel
7.3.2. Canada Central Nervous System Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Application
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End Users
7.3.2.2.5. By Distribution Channel
7.3.3. Mexico Central Nervous System Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Application
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End Users
7.3.3.2.5. By Distribution Channel
8. Europe Central Nervous System Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Application
8.2.3. By Route of Administration
8.2.4. By End Users
8.2.5. By Distribution Channel
8.2.6. By Country (France; Germany; UK; Italy; Spain)
8.3. Europe: Country Analysis
8.3.1. France Central Nervous System Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Application
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End Users
8.3.1.2.5. By Distribution Channel
8.3.2. Germany Central Nervous System Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Application
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End Users
8.3.2.2.5. By Distribution Channel
8.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Application
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End Users
8.3.3.2.5. By Distribution Channel
8.3.4. Italy Central Nervous System Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Application
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By End Users
8.3.4.2.5. By Distribution Channel
8.3.5. Spain Central Nervous System Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Application
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By End Users
8.3.5.2.5. By Distribution Channel
9. Asia-Pacific Central Nervous System Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Application
9.2.3. By Route of Administration
9.2.4. By End Users
9.2.5. By Distribution Channel
9.2.6. By Country (China; India; Japan; South Korea; Australia)
8.3 Asia-Pacific: Country Analysis
8.3.1 China Central Nervous System Therapeutics Market Outlook
8.3.1.1 Market Size & Forecast
8.3.1.1.1 By Value
8.3.1.2 Market Share & Forecast
8.3.1.2.1 By Drug Class
8.3.1.2.2 By Application
8.3.1.2.3 By Route of Administration
8.3.1.2.4 By End Users
8.3.1.2.5 By Distribution Channel
8.3.2 India Central Nervous System Therapeutics Market Outlook
8.3.2.1 Market Size & Forecast
8.3.2.1.1 By Value
8.3.2.2 Market Share & Forecast
8.3.2.2.1 By Drug Class
8.3.2.2.2 By Application
8.3.2.2.3 By Route of Administration
8.3.2.2.4 By End Users
8.3.2.2.5 By Distribution Channel
8.3.3 Japan Central Nervous System Therapeutics Market Outlook
8.3.3.1 Market Size & Forecast
8.3.3.1.1 By Value
8.3.3.2 Market Share & Forecast
8.3.3.2.1 By Drug Class
8.3.3.2.2 By Application
8.3.3.2.3 By Route of Administration
8.3.3.2.4 By End Users
8.3.3.2.5 By Distribution Channel
8.3.4 South Korea Central Nervous System Therapeutics Market Outlook
8.3.4.1 Market Size & Forecast
8.3.4.1.1 By Value
8.3.4.2 Market Share & Forecast
8.3.4.2.1 By Drug Class
8.3.4.2.2 By Application
8.3.4.2.3 By Route of Administration
8.3.4.2.4 By End Users
8.3.4.2.5 By Distribution Channel
8.3.5 Australia Central Nervous System Therapeutics Market Outlook
8.3.5.1 Market Size & Forecast
8.3.5.1.1 By Value
8.3.5.2 Market Share & Forecast
8.3.5.2.1 By Drug Class
8.3.5.2.2 By Application
8.3.5.2.3 By Route of Administration
8.3.5.2.4 By End Users
8.3.5.2.5 By Distribution Channel
10. Middle East and Africa Central Nervous System Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Application
10.2.3. By Route of Administration
10.2.4. By End Users
10.2.5. By Distribution Channel
10.2.6. By Country (UAE; Saudi Arabia; South Africa)
10.3. MEA: Country Analysis
10.3.1. South Africa Central Nervous System Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Application
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By End Users
10.3.1.2.5. By Distribution Channel
10.3.2. Saudi Arabia Central Nervous System Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Application
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By End Users
10.3.2.2.5. By Distribution Channel
10.3.3. UAE Central Nervous System Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Application
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By End Users
10.3.3.2.5. By Distribution Channel
11. South America Central Nervous System Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Application
11.2.3. By Route of Administration
11.2.4. By End Users
11.2.5. By Distribution Channel
11.2.6. By Country (Brazil; Argentina; Colombia)
11.3. South America: Country Analysis
11.3.1. Brazil Central Nervous System Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Application
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By End Users
11.3.1.2.5. By Distribution Channel
11.3.2. Argentina Central Nervous System Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Application
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By End Users
11.3.2.2.5. By Distribution Channel
11.3.3. Colombia Central Nervous System Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Drug Class
11.3.3.2.3. By Application
11.3.3.2.4. By Route of Administration
11.3.3.2.5. By End Users
11.3.3.2.6. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2. Global Players Profiled (Leading Companies)
14.2.1. Eli Lilly and Company Ltd.
14.2.2. Merck & Co. Inc.
14.2.3. AstraZeneca PLC
14.2.4. Novartis AG
14.2.5. Teva Pharmaceutical Industries Ltd.
14.2.6. F. Hoffmann-La Roche AG
14.2.7. Biogen Inc.
14.2.8. Pfizer Inc.
14.2.9. GlaxoSmithKline PLC
14.2.10. Otsuka Holdings Co. Ltd.
14.2.11. Johnson & Johnson Services Inc.
14.2.12. Sanofi SA
14.2.13. Bristol Myers Squibb Pharmaceuticals Ltd.
14.2.14. Bayer AG
14.2.15. Amgen Inc.
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eli Lilly and Company Ltd.
  • Merck & Co. Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche AG
  • Biogen Inc.
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Otsuka Holdings Co. Ltd.
  • Johnson & Johnson Services Inc.
  • Sanofi SA
  • Bristol Myers Squibb Pharmaceuticals Ltd.
  • Bayer AG
  • Amgen Inc.